Kenvue heads into its May 7 Q1 2026 earnings release with shorts retreating and borrow conditions that offer little drama — but analysts have spent the past month quietly lowering the bar.
Short sellers have been cutting exposure ahead of the print. Short interest has fallen roughly 8% over the past month to 3.0% of free float — a level too modest to frame as a meaningful bear thesis. Borrow remains effortless: availability is extremely loose and cost to borrow is just 0.44%, up from recent troughs but still near rock-bottom on a historical basis. The ORTEX short score is a mild 32, well below levels that would signal any concentrated bearish conviction. Options positioning is also calm. The put/call ratio of 0.42 runs marginally above its 20-day average of 0.41 but with a z-score below 1.0, it points to neither hedging pressure nor unusual bullish bets. The stock itself has drifted, down 0.3% on the week at $17.43, after a roughly flat year-to-date performance of just over 1%.
The more interesting signal is the drift lower in analyst price targets. Three firms — UBS, Barclays, and Citigroup — all trimmed their targets in April, each landing in the $18–$19 range against a mean target of $19.58. No ratings changed hands; the moves look more like macro-driven valuation resets than fundamental downgrades. The consensus is cautious rather than hostile: analysts see about 12% upside from current levels but aren't rushing to make the bull case. The stock trades at roughly 15x earnings and 11.2x EV/EBITDA, multiples that have compressed modestly over the past 30 days. One contrarian note worth watching: the 90-day EPS momentum factor scores in the 71st percentile, suggesting estimate revisions have been tracking higher even as targets come in — a mild divergence between analyst caution and the underlying earnings trend.
Ownership offers one genuinely active subplot. Pentwater Capital built a position of 56.7 million shares (around 3% of the company) from essentially nothing as of its last filing — a meaningful accumulation that signals at least one active manager sees a value case at current prices. The top three passive holders (Vanguard, BlackRock, State Street) between them own over 26% of shares, providing a stable base. Insider activity through March has been immaterial: small equity award-related sells from mid-level management, none significant enough to read as a directional signal.
After three consecutive earnings prints in which the stock barely moved — gains of less than 1% on the day and under 4% over five days — the May 7 release is a test of whether the EPS momentum can outrun the reset in analyst targets, and whether Kenvue's consumer health portfolio shows any volume recovery against a cautious macro backdrop.
See the live data behind this article on ORTEX.
Open KVUE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
